85 related articles for article (PubMed ID: 3902205)
1. A prospective study of detorubicin in malignant mesothelioma.
Colbert N; Vannetzel JM; Izrael V; Schlienger M; Milleron B; Blanchon F; Herman D; Akoun G; Roland J; Chatelet F
Cancer; 1985 Nov; 56(9):2170-4. PubMed ID: 3902205
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of pirarubicin in malignant pleural mesothelioma.
Kaukel E; Koschel G; Gatzemeyer U; Salewski E
Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
[TBL] [Abstract][Full Text] [Related]
4. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide in malignant mesothelioma: a phase II study.
Andersen MK; Krarup-Hansen A; Mårtensson G; Winther-Nielsen H; Thylen A; Damgaard K; Olling S; Wallin J
Lung Cancer; 1999 Apr; 24(1):39-43. PubMed ID: 10403693
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
7. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
Mintzer DM; Kelsen D; Frimmer D; Heelan R; Gralla R
Cancer Treat Rep; 1985 Jun; 69(6):711-2. PubMed ID: 4040424
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
[TBL] [Abstract][Full Text] [Related]
11. Vindesine in the treatment of malignant mesothelioma: a phase II study.
Kelsen D; Gralla R; Cheng E; Martini N
Cancer Treat Rep; 1983 Sep; 67(9):821-2. PubMed ID: 6883358
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
[TBL] [Abstract][Full Text] [Related]
13. Detorubicin--an active anthracycline in untreated metastatic melanoma.
Chawla SP; Legha SS; Benjamin RS
J Clin Oncol; 1985 Nov; 3(11):1529-34. PubMed ID: 4056844
[TBL] [Abstract][Full Text] [Related]
14. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
15. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
Yogelzang NJ; Herndon JE; Cirrincione C; Harmon DC; Antman KH; Corson JM; Suzuki Y; Citron ML; Green MR
Cancer; 1997 Jun; 79(11):2237-42. PubMed ID: 9179072
[TBL] [Abstract][Full Text] [Related]
16. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
[TBL] [Abstract][Full Text] [Related]
17. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
Kindler HL; Herndon JE; Zhang C; Green MR;
Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
[TBL] [Abstract][Full Text] [Related]
19. Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma.
Sridhar KS; Hussein AM; Feun LG; Zubrod CG
Cancer; 1989 Mar; 63(6):1084-91. PubMed ID: 2917312
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH
J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
